HC Wainwright Reaffirms Buy Rating on Hemab Therapeutics
HC Wainwright maintains its buy rating on Hemab Therapeutics with a $40 price target.
Key Points
- HC Wainwright reiterated a buy rating on Hemab Therapeutics, setting a $40 price target on June 17, 2026.
- Hemab Therapeutics shares are trading around $25.51, with a market cap of approximately $1.17 billion and a forward P/E of -11.38.
- Analysts have a strong buy consensus on Hemab, with a mean price target of $41.75 among four opinions.
On June 17, 2026, HC Wainwright reiterated its buy rating for Hemab Therapeutics Holdings, Inc. (NasdaqGS:COAG) and set a price target of $40. Analyst Emily Bodnar's reaffirmation suggests confidence in the company's potential.
Analysts Set New Price Targets
On June 17, 2026, HC Wainwright & Co. reiterated its buy rating on Hemab Therapeutics with a $40 price target. This aligns with other recent analyst activities, with Wedbush, Jefferies, Evercore ISI Group, and Goldman Sachs all initiating coverage with buy ratings and price targets ranging from $36 to $50 in late May 2026. The consensus among analysts is a strong buy, with a mean target price of $41.75 from four analyst opinions.
Hemab Therapeutics Stock Snapshot
Shares of Hemab Therapeutics (NasdaqGS:COAG) are currently trading around $25.51. The company has a market capitalization of about $1.17 billion. Despite not being profitable, its forward price-to-earnings ratio stands at -11.38. The stock's 52-week price range is between $23.00 and $36.61, with both the 50-day and 200-day moving averages at approximately $26.63. Hemab maintains a strong liquidity position, with a current ratio of 18.03 and a quick ratio of 17.62.
About Hemab Therapeutics
Hemab Therapeutics Holdings, Inc. is a biotechnology company focused on developing innovative therapies for blood coagulation disorders. Based in Cambridge, Massachusetts, and founded in 2020, the company is led by CEO Dr. Benny Sorensen. Hemab's pipeline includes HMB-001, a bispecific antibody in Phase 1/2 trials for Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002, a monovalent antibody for Von Willebrand disease. The company operates in the U.S. and Denmark, advancing several preclinical and discovery-stage assets.
Bottom Line
HC Wainwright's reiterated buy rating and $40 price target for Hemab Therapeutics highlight ongoing confidence in the company's prospects. With shares trading at $25.51 and a market cap of $1.17 billion, the stock remains a focus for investors tracking the biotechnology sector. As a reminder, analyst ratings and targets reflect professional opinions and are subject to change based on future developments.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.